Skip to content
Screener

Similar metrics at other companies

Micron Technology logo
MUAll other — R&D
$0-100%
Alarm.com Holdings logo
ALRMOther — R&D
$10.79M+38.1%
Aquestive Therapeutics, Inc. logo
AQSTOther — R&D
$319K-41.6%
Insmed logo
INSMOther external R&D expenses — R&D
$48.84M+71.7%
Veradermics logo
MANER&D
$20.93M+82.8%
Polaryx Therapeutics, Inc. logo
PLYXR&D
$679K-85.6%

Other financials

Income statement

See full
Revenue$330.4M+123%
Gross profit$157.9M+128%
Operating income$68.3M+1,220%
Net income$57.4M+1,846%
EPS (diluted)$1.07+1,883%

Balance sheet

See full
Cash & equivalents$240.5M+354%
Total debt$38.1M+4.9%
Total equity$912.0M+8.9%
Total assets$1.3B+17.3%

Cash flow

See full
Operating cash flow$45.2M+626%
CapEx$4.3M+105%
Free cash flow$40.9M+890%

Valuation

See full
Market cap$4.91B+190%
Enterprise value$4.71B+181%
P/E42.4×
P/S5.2×+2.6×

Profitability

See full
Gross margin48.2%+5.0pp
Operating margin-0.6%-0.3pp
Net margin12.2%
FCF margin11.1%+6.0pp

Returns & leverage

See full
Return on equity13.2%
Debt / equity0.0×
Current ratio3.4×-1.5×

Where this comes from

Reported directly by Kulicke & Soffa Industries in its filing.

Tagged under the XBRL concept klic:ResearchAndDevelopmentExpenseIncludingImpairmentChargesAndGainRelatingToCessationOfBusiness.

The source filing: Kulicke & Soffa Industries’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:51 AM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q3 2026
Accession
0000056978-26-000032
(in thousands)Three months ended July 4, 2026 / Reportable segments / Ball Bonding EquipmentThree months ended July 4, 2026 / Reportable segments / Wedge Bonding EquipmentThree months ended July 4, 2026 / Reportable segments / Advanced SolutionsThree months ended July 4, 2026 / Reportable segments / APSThree months ended July 4, 2026 / Reconciling items / All OthersThree months ended July 4, 2026 / Reconciling items / Unallocated Corporate ExpensesThree months ended July 4, 2026 / Total Company
Net Revenue$226,068$25,777$29,415$35,772$13,377$330,409
Cost of sales111,46214,78619,20417,5229,45630172,460
Selling, general and administrative9,6002,5914,7653,3392,10023,37445,769
Research and development11,7996,91817,9993,2102,2651,72343,914
Total operating expenses21,3999,50922,7646,5494,36525,09789,683
Income / (Loss) from operations$93,207$1,482$(12,553)$11,701$(444)$(25,127)$68,266

Item 1. – FINANCIAL STATEMENTS

FAQ

What is Kulicke & Soffa Industries's all others — R&D?
Kulicke & Soffa Industries (KLIC) reported all others — R&D of $2.27M in Q2 2026.
How has Kulicke & Soffa Industries's all others — R&D changed year-over-year?
Kulicke & Soffa Industries's all others — R&D decreased by 55.8% year-over-year, from $5.13M to $2.27M.
What does all others — R&D mean?
Captures the expenditures dedicated to innovation, product development, and technological advancement within the 'All Others' segment. This investment is critical for maintaining long-term competitiveness and driving future product cycles for the segment. Investors monitor this to gauge the company's commitment to evolving its non-core product portfolio.

Ask your AI about Kulicke & Soffa Industries's all others — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude